logo
  

Quest Diagnostics Raises 2021 Guidance - Quick Facts

Quest Diagnostics Incorporated (DGX) has updated its financial outlook for full year 2021. The company said COVID-19 molecular testing volumes were stronger than expected through the end of August and are anticipated to continue to be stronger than projected because of the surge of the Delta variant.

For full year 2021, adjusted earnings per share now expected to be $11.65-$12.35 compared to the previous outlook of $10.65-$11.35. Revenues are now expected to be $9.84-$10.09 billion compared to the prior outlook of $9.54-$9.79 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $11.38 on revenue of $9.79 billion. Analysts' estimates typically exclude special items.

For 2021, the company now expects reported earnings per share to be $12.54-$13.24 compared to the previous outlook of $11.48-$12.18. Cash provided by operations are now expected to be at least $2.0 billion compared to the prior outlook of at least $1.9 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT